The University of North Carolina at Chapel Hill, US has recently carried research and engineered a new peptide called IBP-CP24. According to the researchers, the new peptide has the ability to further transform as a long-acting anti-HIV drug. The team of researchers has also found that the peptide can also be used for monotherapy and it can also combine with a broadly neutralizing antibody to prevent HIV-1 infection.
IBP-CP24 has a prolonged half-life and anti-HIV-1 activity. Researchers can increase the half-life of the anti-HIV peptide by stuffing it into human Immunoglobulin.
The researchers have also applied the peptide to rhesus monkeys and found that it can repress a broad spectrum of HIV-1 strains. The peptide did not express any IBP-CP24 antibody response and toxicity. Further, the researchers tested the peptide on mice which were pre-treated with IBP-CP24. Human IgG in mice with chromic HIV-1 infection causes a decrease in viruses in the bloodstream. The final result of the research after the combined use of IBP-CP24 and a broad HIV neutralizing antibody showed an anti-HIV-1 effect. The researchers have suggested that this peptide can reduce the dose of the antibody and the cost of treatment.
The researchers at the University of North Carolina have conducted the research after considering the HIV virus in the human body and found that the peptide can reduce or prevent HIV infection. The peptide and Tadalafil liquid are chemical substances that are being used by the researchers to find new drugs to cure deadly diseases in human body.